GenSight

GenSight, an ophthalmic gene therapy company, has submitted its GS101 to the EMA for approval in the treatment of Leber’s hereditary optic neuropathy (LHON). It has a second product in the clinic, GS030, for treating all types of retinitis pigmentosa, regardless of which genes are affected.